Evidence map›Paper›PMID 36106155›Full record

ArticleJournal of virus eradication2022

The ethical case for placebo control in HIV-cure-related studies with ART interruption.

Monica Magalhaes, Daniel R Kuritzkes, Nir Eyal

Abstract read
In one paragraph

Article in Journal of virus eradication, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Monica MagalhaesCenter for Population-Level Bioethics, Rutgers University, New Brunswick, NJ, USA.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Nir EyalCenter for Population-Level Bioethics, Rutgers University, New Brunswick, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies that seek to cure HIV must ask participants to interrupt their antiretroviral treatment. In such circumstances, is it permissible to include a placebo group in the study? We explain why doing so is a scientific and an ethical necessity, and more benign than imagined.

Indexed as

Analytic treatment interruptionHIV Cure-related studiesHuman subjects researchPlacebosResearch ethics

Identifiers

PMID36106155
PMCPMC9464947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.